نتایج جستجو برای: cyp2c9 and vkorc1 polymorphisms

تعداد نتایج: 16835218  

Journal: :Pharmacogenomics 2016
Niclas Eriksson Lars Wallentin Lars Berglund Tomas Axelsson Stuart Connolly John Eikelboom Michael Ezekowitz Jonas Oldgren Guillaume Paré Paul Reilly Agneta Siegbahn Ann-Christine Syvanen Claes Wadelius Salim Yusuf Mia Wadelius

AIMS We investigated associations between genetic variation in candidate genes and on a genome-wide scale with warfarin maintenance dose, time in therapeutic range (TTR), and risk of major bleeding. MATERIALS & METHODS In total, 982 warfarin-treated patients from the RE-LY trial were studied. RESULTS After adjusting for SNPs in VKORC1 and CYP2C9, SNPs in DDHD1 (rs17126068) and NEDD4 (rs2288...

2014
Takashi Tamura Nobuyuki Katsuda Nobuyuki Hamajima

Warfarin is widely prescribed for patients with the risk of thromboembolism around the world. The inter-individual and inter-racial differences in appropriate dosage depend highly on age, body weight, and genetic factors. A lot of studies including genome-wide association studies revealed that vitamin K epoxide reductase complex, subunit 1 (VKORC1) G-1639A and Cytochrome P450 (CYP) 2C9 A1075C a...

2012
Hong-Juan Wang Cong Ma Jie Yang Qiang Xu Yan Zhang Lei Gao Bin Xu Yu-Xiao Zhang Yang Li Tong Yin

Warfarin is a commonly used anticoagulant with a narrow therapeutic range and risk of hemorrhagic complications. After CYP2C9 and VKORC1, CYP4F2 was confirmed as the third principle genetic determinant of warfarin dose variability. CYP4F2 functions as a vitamin K1 (VK1) oxidase, a counterpart to vitamin K oxidize reductase (encoded by VKORC1) in limiting excessive accumulation of VK1 in vitamin...

Journal: :Blood 2007
Eric A Millican Petra A Lenzini Paul E Milligan Leonard Grosso Charles Eby Elena Deych Gloria Grice John C Clohisy Robert L Barrack R Stephen J Burnett Deepak Voora Susan Gatchel Amy Tiemeier Brian F Gage

High variability in drug response and a narrow therapeutic index complicate warfarin therapy initiation. No existing algorithm provides recommendations on refining the initial warfarin dose based on genetic variables, clinical data, and international normalized ratio (INR) values. Our goal was to develop such an algorithm. We studied 92 patients undergoing primary or revision total hip or knee ...

Journal: :Acta Cardiologica Sinica 2013
Ming-Shien Wen Ming Ta Michael Lee

UNLABELLED Warfarin was first introduced in the 1950s and quickly became the most commonly used oral anticoagulant for the prevention of thromboembolism in patients with deep vein thrombosis, atrial fibrillation, or prosthetic heart valve replacement. Warfarin is highly effective in treating these diseases; however, several factors prevent it from even wider use, especially in Asian populations...

Journal: :Thrombosis Journal 2009
Claudia C Branco Tânia Pereirinha Rita Cabral Paula R Pacheco Luisa Mota-Vieira

SUMMARY BACKGROUND The Azorean population presents the highest standardized mortality rate for cardiovascular diseases (CVD) when compared to mainland Portugal and other populations. Since thrombosis is a common cause of CVD, we assessed four polymorphisms in three thrombotic risk genes - F5 (G1691A), F2 (G20210A) and MTHFR (C677T, A1298C), in 469 healthy blood donors from São Miguel Island ...

Journal: :Pharmacological reports : PR 2014
Risha Nahar Renu Saxena Roumi Deb Rajiv Parakh Sujay Shad Prahlad K Sethi Parul Takkar Ishwar C Verma

AIMS The study aims to evaluate the impact of genetic, demographic and clinical data on various measures of outcome of anticoagulation quality in patients. PATIENTS AND METHODS The study consisted of 310 patients receiving long-term oral anticoagulation therapy in our hospital. Apart from demographic and clinical variables, 21 SNPs (in 7 genes) were analyzed and compared with the outcomes of ...

Journal: :Human molecular genetics 2010
Pei-Chieng Cha Taisei Mushiroda Atsushi Takahashi Michiaki Kubo Shiro Minami Naoyuki Kamatani Yusuke Nakamura

Warfarin is a commonly used anticoagulant, whose dose needs to be determined for each individual patient owing to large inter-individual variability in its therapeutic dose. Although several clinical and genetic variables influencing warfarin dose have been identified, uncovering additional factors are critically important for safer use of warfarin. Through a genome-wide association study, we i...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید